JP2014533279A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014533279A5 JP2014533279A5 JP2014541315A JP2014541315A JP2014533279A5 JP 2014533279 A5 JP2014533279 A5 JP 2014533279A5 JP 2014541315 A JP2014541315 A JP 2014541315A JP 2014541315 A JP2014541315 A JP 2014541315A JP 2014533279 A5 JP2014533279 A5 JP 2014533279A5
- Authority
- JP
- Japan
- Prior art keywords
- fragment
- antibody
- use according
- cycle
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161557815P | 2011-11-09 | 2011-11-09 | |
| US61/557,815 | 2011-11-09 | ||
| US201161569113P | 2011-12-09 | 2011-12-09 | |
| US61/569,113 | 2011-12-09 | ||
| PCT/US2012/064395 WO2013071068A2 (en) | 2011-11-09 | 2012-11-09 | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014533279A JP2014533279A (ja) | 2014-12-11 |
| JP2014533279A5 true JP2014533279A5 (enExample) | 2015-12-24 |
| JP6541350B2 JP6541350B2 (ja) | 2019-07-10 |
Family
ID=47179025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541315A Expired - Fee Related JP6541350B2 (ja) | 2011-11-09 | 2012-11-09 | 抗ｃｘｃｒ４抗体による血液悪性腫瘍の処置 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10428151B2 (enExample) |
| EP (1) | EP2776032B1 (enExample) |
| JP (1) | JP6541350B2 (enExample) |
| KR (1) | KR102024957B1 (enExample) |
| CN (1) | CN104039320B (enExample) |
| AU (1) | AU2012335553B2 (enExample) |
| BR (1) | BR112014011144A2 (enExample) |
| CA (1) | CA2855155A1 (enExample) |
| CY (1) | CY1121331T1 (enExample) |
| DK (1) | DK2776032T3 (enExample) |
| EA (1) | EA026153B1 (enExample) |
| ES (1) | ES2705001T3 (enExample) |
| HR (1) | HRP20182183T1 (enExample) |
| HU (1) | HUE043001T2 (enExample) |
| IL (1) | IL232517B (enExample) |
| LT (1) | LT2776032T (enExample) |
| MX (1) | MX357100B (enExample) |
| PL (1) | PL2776032T3 (enExample) |
| PT (1) | PT2776032T (enExample) |
| RS (1) | RS58102B1 (enExample) |
| SG (1) | SG11201401386XA (enExample) |
| SI (1) | SI2776032T1 (enExample) |
| SM (1) | SMT201900026T1 (enExample) |
| WO (1) | WO2013071068A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA018836B1 (ru) * | 2006-10-02 | 2013-11-29 | Медарекс, Л.Л.К. | Человеческие антитела, которые связываются с cxcr4, и их применение |
| ES2624981T3 (es) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario |
| CA2920377A1 (en) * | 2013-08-05 | 2015-02-12 | Cambridge Enterprise Limited | Inhibition of cxcr4 signaling in cancer immunotherapy |
| CA2922398C (en) * | 2013-09-12 | 2023-08-29 | Dana-Farber Cancer Institute, Inc. | Methods for evaluating and treating waldenstrom's macroglobulinemia |
| ES2742079T3 (es) * | 2013-11-06 | 2020-02-13 | Bristol Myers Squibb Co | Tratamiento de macroglobulinemia de Waldenström asociada a C1013G/CXCR4 con un anticuerpo anti-CXCR4 |
| EP3077001B1 (en) | 2013-12-06 | 2020-04-15 | Dana-Farber Cancer Institute, Inc. | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
| AU2014361798B2 (en) | 2013-12-13 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| CN106062002B (zh) * | 2013-12-17 | 2021-05-04 | 埃姆医疗有限公司 | 抵抗骨髓增生障碍或淋巴组织增生障碍的手段和方法 |
| WO2015118538A1 (en) | 2014-02-06 | 2015-08-13 | Yeda Research And Development Co. Ltd. | Anti cd84 antibodies, compositions comprising same and uses thereof |
| CN106794219A (zh) * | 2014-02-19 | 2017-05-31 | 北京迈康斯德医药技术有限公司 | 趋化因子受体拮抗体及其联合疗法 |
| EP3242685B1 (en) * | 2015-01-09 | 2022-05-04 | AdAlta Limited | Cxcr4 binding molecules |
| SG11201708223QA (en) | 2015-04-17 | 2017-11-29 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CN108026173A (zh) | 2015-06-12 | 2018-05-11 | 百时美施贵宝公司 | 通过联合阻断pd-1和cxcr4信号传导途径治疗癌症 |
| CN116196426A (zh) | 2015-07-16 | 2023-06-02 | 百欧肯治疗有限公司 | 治疗癌症的组合物及方法 |
| JP6933379B2 (ja) * | 2015-09-24 | 2021-09-08 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 転移を低減するための方法および組成物 |
| EP3373929A4 (en) * | 2015-11-09 | 2019-07-03 | The General Hospital Corporation d/b/a Massachusetts General Hospital | UNIT DOSE FORMULATIONS FOR USE AS ANTI-FUGETACTIC AGENT |
| AU2017222495B2 (en) * | 2016-02-23 | 2019-08-08 | Biolinerx Ltd. | Methods of treating acute myeloid leukemia |
| CN109152781A (zh) | 2016-04-29 | 2019-01-04 | 达纳-法伯癌症研究所有限公司 | 作为myd88突变疾病中的治疗靶标的hck |
| JP7169195B2 (ja) | 2016-05-20 | 2022-11-10 | バイオヘイブン・ファーマシューティカル・ホールディング・カンパニー・リミテッド | 癌を処置するためのリルゾール、リルゾールプロドラッグまたはリルゾール類似体と免疫療法との併用 |
| US20190175557A1 (en) * | 2016-06-16 | 2019-06-13 | Centre National De La Recherche Scientifique | Compounds useful for decreasing interferon level |
| NZ789594A (en) | 2016-06-20 | 2025-07-25 | Kymab Ltd | Anti-PD-L1 antibodies |
| CN110234352A (zh) * | 2017-01-31 | 2019-09-13 | Msm蛋白质技术公司 | 抗cxcr4抗体 |
| KR102003179B1 (ko) * | 2017-02-21 | 2019-07-23 | 쿠라 온콜로지, 인크. | 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법 |
| AU2018243754B2 (en) | 2017-03-31 | 2025-04-10 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20200064132A (ko) | 2017-10-15 | 2020-06-05 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하는 방법 |
| WO2019113456A1 (en) * | 2017-12-08 | 2019-06-13 | The Medical College Of Wisconsin, Inc. | Chemokine variants as immune stimulants |
| US20230181635A1 (en) * | 2018-03-13 | 2023-06-15 | Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz | Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy |
| EP3768715A1 (en) | 2018-03-23 | 2021-01-27 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| US20210024873A1 (en) | 2018-03-27 | 2021-01-28 | Bristol-Myers Squibb Company | Real-time monitoring of protein concentration using ultraviolet signal |
| WO2019191676A1 (en) | 2018-03-30 | 2019-10-03 | Bristol-Myers Squibb Company | Methods of treating tumor |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| CN114245869A (zh) | 2019-05-23 | 2022-03-25 | 百时美施贵宝公司 | 监测细胞培养基的方法 |
| KR20230080460A (ko) | 2020-10-05 | 2023-06-07 | 브리스톨-마이어스 스큅 컴퍼니 | 단백질을 농축시키는 방법 |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| US20250188152A1 (en) | 2022-03-09 | 2025-06-12 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
| TW202444754A (zh) * | 2023-01-30 | 2024-11-16 | 英商凱麥博有限公司 | 抗體 |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
| CN119119196B (zh) * | 2024-08-01 | 2025-09-09 | 青岛大学 | 一种基于Motixafortide-喜树碱缀合物及其制备方法和应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| JP3367581B2 (ja) | 1993-10-14 | 2003-01-14 | 小野薬品工業株式会社 | 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｄｎａ、そのｄｎａからなるベクター、そのベクターで形質転換された宿主細胞 |
| US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
| CN101940189A (zh) | 2000-11-30 | 2011-01-12 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
| US7674618B2 (en) | 2003-09-04 | 2010-03-09 | Medarex, Inc. | Expression vector |
| EP1871807B1 (en) | 2005-02-18 | 2012-11-28 | Dana-Farber Cancer Institute, Inc. | Antibodies against cxcr4 and methods of use thereof |
| US8569280B2 (en) * | 2005-04-25 | 2013-10-29 | Immune Disease Institute | Methods for the treatment of multiple myeloma |
| DK2029155T3 (en) * | 2006-02-28 | 2016-08-01 | Pharma Mar Sa | IMPROVED treatment of multiple myeloma |
| EA018836B1 (ru) * | 2006-10-02 | 2013-11-29 | Медарекс, Л.Л.К. | Человеческие антитела, которые связываются с cxcr4, и их применение |
| FR2915102B1 (fr) | 2007-04-23 | 2014-05-16 | Pf Medicament | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer |
| MX2010012435A (es) * | 2008-05-14 | 2011-05-03 | Lilly Co Eli | Anticuerpos anti-cxcr4. |
| WO2010043650A2 (en) | 2008-10-14 | 2010-04-22 | Ablynx Nv | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| EP2405916B1 (en) * | 2009-03-12 | 2018-02-07 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| AR076590A1 (es) * | 2009-05-19 | 2011-06-22 | Vivia Biotech Sl | Metodos para proveer pruebas medicinales personalizada ex vivo para neoplasmas hematologicos |
| EA201390144A1 (ru) | 2010-08-20 | 2013-06-28 | Серулин Фарма Инк. | Конъюгаты терапевтический пептид-полимер, частицы, композиции и связанные с ними способы |
-
2012
- 2012-11-09 EP EP12787343.8A patent/EP2776032B1/en active Active
- 2012-11-09 US US14/356,996 patent/US10428151B2/en active Active
- 2012-11-09 DK DK12787343.8T patent/DK2776032T3/en active
- 2012-11-09 KR KR1020147012396A patent/KR102024957B1/ko not_active Expired - Fee Related
- 2012-11-09 CA CA2855155A patent/CA2855155A1/en not_active Abandoned
- 2012-11-09 PT PT12787343T patent/PT2776032T/pt unknown
- 2012-11-09 PL PL12787343T patent/PL2776032T3/pl unknown
- 2012-11-09 JP JP2014541315A patent/JP6541350B2/ja not_active Expired - Fee Related
- 2012-11-09 RS RS20181552A patent/RS58102B1/sr unknown
- 2012-11-09 MX MX2014005267A patent/MX357100B/es active IP Right Grant
- 2012-11-09 WO PCT/US2012/064395 patent/WO2013071068A2/en not_active Ceased
- 2012-11-09 HU HUE12787343A patent/HUE043001T2/hu unknown
- 2012-11-09 CN CN201280066551.7A patent/CN104039320B/zh not_active Expired - Fee Related
- 2012-11-09 AU AU2012335553A patent/AU2012335553B2/en not_active Ceased
- 2012-11-09 SI SI201231459T patent/SI2776032T1/sl unknown
- 2012-11-09 SG SG11201401386XA patent/SG11201401386XA/en unknown
- 2012-11-09 ES ES12787343T patent/ES2705001T3/es active Active
- 2012-11-09 BR BR112014011144A patent/BR112014011144A2/pt not_active Application Discontinuation
- 2012-11-09 SM SM20190026T patent/SMT201900026T1/it unknown
- 2012-11-09 HR HRP20182183TT patent/HRP20182183T1/hr unknown
- 2012-11-09 LT LTEP12787343.8T patent/LT2776032T/lt unknown
- 2012-11-09 EA EA201490957A patent/EA026153B1/ru not_active IP Right Cessation
-
2014
- 2014-05-08 IL IL232517A patent/IL232517B/en active IP Right Grant
-
2019
- 2019-01-15 CY CY20191100051T patent/CY1121331T1/el unknown
- 2019-10-01 US US16/590,152 patent/US20200231683A1/en not_active Abandoned